Fan, junliang – Trademark Portfolio

Entity Type: 01

Fan, junliang holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 31 (Natural Agricultural Products) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include IDOLYFAN. The owner is based in Shenzhen,Guangdong.

3A3105, District 7, One City Center

Shenzhen,Guangdong 518000 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

IDOLYFAN
IDOLYFAN
Registered 2022
IDOLYFAN
IDOLYFAN
Registered 2022

Trademark Classifications

Fan, junliang's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

31
Natural Agricultural Products (1 filing)

Raw and unprocessed agricultural, aquacultural, horticultural and forestry products

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Fan, junliang have?

Fan, junliang has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does Fan, junliang file in?

Fan, junliang files trademarks across 2 Nice Classification classes. The most active classes are Class 31 (Natural Agricultural Products), Class 5 (Pharmaceuticals). Class 31 covers raw and unprocessed agricultural, aquacultural, horticultural and forestry products.

What are Fan, junliang's most well-known trademarks?

Fan, junliang's registered trademark portfolio includes well-known marks such as IDOLYFAN. These are among 2 currently registered trademarks in the portfolio.

What is Fan, junliang's trademark registration success rate?

Fan, junliang has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.